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Objectives. Published reports were reviewed to evaluate the
characteristics of peripartal management and the late pregnancy
outcome in women with pulmonary vascular disease (PVD).
Background. Pulmonary hypertension poses one of the highest
risks for maternal mortality, but actual data on the maternal and
neonatal prognosis in this group are lacking.
Methods. Reports published from 1978 through 1996 of Eisen-
menger’s syndrome (n 5 73), primary pulmonary hypertension
(PPH) (n 5 27) and secondary vascular pulmonary hypertension
(SVPH) (n 5 25) complicating late pregnancy were included and
analyzed using logistic regression analysis.
Results. Maternal mortality was 36% in Eisenmenger’s syn-
drome, 30% in PPH and 56% (p < 0.08 vs. other two groups) in
SVPH. Except for three prepartal deaths due to Eisenmenger’s
syndrome, all fatalities occurred within 35 days after delivery.
Neonatal survival ranging from 87% to 89% was similar in the
three groups. Previous pregnancies, timing of the diagnosis and
hospital admission, operative delivery and diastolic pulmonary
artery pressure were significant univariate (p < 0.05) maternal
risk factors. Late diagnosis (p 5 0.002, odds ratio 5.4) and late
hospital admission (p 5 0.01, odds ratio 1.1 per week of preg-
nancy) were independent predictive risk factors of maternal
mortality.
Conclusions. In the last two decades maternal mortality was
comparable in patients with Eisenmenger’s syndrome and PPH;
however, it was relevantly higher in SVPH. Maternal prognosis
depends on the early diagnosis of PVD, early hospital admission,
individually tailored treatment during pregnancy and medical
therapy and care focused on the postpartal period.
(J Am Coll Cardiol 1998;31:1650–7)
©1998 by the American College of Cardiology
Preexistence or gestational occurrence of pulmonary vascular
disease (PVD) is one of the rare conditions unequivocally
considered to pose an extreme risk of maternal death. The
poor tolerance during pregnancy seems to result from a low,
pregnancy-independent exercise capacity superimposed on the
gestational cardiovascular demands, insufficient adaptation of
the right heart and poorly compliant pulmonary vasculature
(1–5). Pregnancy prevention and early interruption became
and still are the relevant measures for improving long-term
survival in women of childbearing age with PVD (6). The last
large-scale review of outcome in pregnant women with Eisen-
menger’s syndrome was published in 1979 (7); however, actual
data on the outcome of late pregnancy in women with other
types of PVD are lacking. Published reports from the two
decades were reviewed to evaluate the influence of peripartal
management and outcome of late pregnancy in women with
PVD.
Methods
Material selection. The data base of the National Library
of Medicine (MEDLINE) was used to identify the cases,
published in any language from January 1978 to December
1996, of PVD complicating late pregnancy. The key words
pregnancy, pulmonary hypertension, primary pulmonary hyper-
tension (PPH), pulmonary vasculitis, pulmonary vascular dis-
ease, congenital heart disease, Eisenmenger’s complex and Eisen-
menger’s syndrome were used. The reference list of all journal
articles and recent book chapters was reviewed. The cases of
late pregnancy (beyond 22 weeks and described with the
intention to continue the pregnancy) were separated from
reports of spontaneous abortion or pregnancy interruption.
Only the last reported pregnancy was included in the analysis.
Other types of secondary PVD (e.g., acquired heart, chronic
lung or chest wall diseases) were rejected on an a priori basis.
Eisenmenger’s syndrome was considered if congenital heart
disease, a shunt at any level and pulmonary hypertension
(irrespective of the numerical values) were present. From one
monocentric study (8), only patients with an established diag-
nosis were included; other cases, reported years before the
definitive diagnosis was made, were excluded (8). PPH was
considered if none of the concomitant causes, diseases or
assumed triggers of pulmonary hypertension (9) was men-
tioned. Secondary vascular pulmonary hypertension (SVPH)
comprised a heterogeneous group of patients with the history
From the Department of Anesthesiology, and Department of Biostatistics,
University Hospital, Zurich; and *Division of Cardiology, Inselspital, Bern,
Switzerland.
Manuscript received September 17, 1997; revised manuscript received
February 23, 1998, accepted March 4, 1998.
Address for correspondence: Dr. Branko M. Weiss, Department of Anes-
thesiology, University Hospital Zurich, Ra¨mistrasse 100, CH-8091 Zurich,
Switzerland.
JACC Vol. 31, No. 7
June 1998:1650–7
1650
©1998 by the American College of Cardiology 0735-1097/98/$19.00
Published by Elsevier Science Inc. PII S0735-1097(98)00162-4
or presence of various concomitant diseases, assumed or
recognized triggers and/or autopsy findings of PVD. In some,
pulmonary hypertension was connected with the use of incrim-
inated drugs, in others it was of congenital origin (peripheral
pulmonary artery stenoses) or resulted from thromboembo-
lism, hepatitis, systemic connective tissue or vascular inflam-
matory disease. These cases were grouped together indepen-
dent of etiopathogenesis of PVD and labeled SVPH.
Data analysis. Patient characteristics were presented for
each group, and the details of peripartal management were
separated by maternal outcome. Data were presented as the
number (%) per group, mean value 6 SD and range or, when
appropriate, as median and range. Maternal and fetal/neonatal
mortality or survival were presented as the number (%) of
deaths and exact 95% confidence intervals (CI) for each PVD
group. Logistic regression analysis (SPSS for Windows, Re-
lease 6.0.1., SPSS Inc.), with maternal outcome as the depen-
dent variable, was used univariately for each group and for all
cases. Independent covariates included age, gravida, para,
timing of the diagnosis (before pregnancy vs. late diagnosis, if
PVD was found during pregnancy or after delivery), week of
pregnancy at hospital admission, pulmonary artery pressure
(PAP), hemoglobin and arterial oxygen saturation of hemoglo-
bin (SaO2) values during pregnancy, timing of delivery, mode of
delivery (vaginal vs. operative), type of monitoring (invasive vs.
noninvasive), type of anesthesia (general vs. regional) and use
or nonuse of a pulmonary artery catheter, oxytocic drugs and
antithrombotic drugs. When neonatal outcome was analyzed
as the dependent variable, maternal outcome was included in
the independent covariates. A p value ,0.1 indicated a trend
or potential risk factor. A p value ,0.05 was considered
statistically significant, and the odds ratio (OR) with 95% CI
was calculated to express the predictive relative risk. For
continuous and counting data, risk was expressed per unit of
measurement. Multivariate (stepwise forward) logistic regres-
sion analysis was used to identify the independent risk factors
of maternal mortality. The limit to enter an item into the
multivariate analysis was p , 0.05 in the univariate analysis.
Results
Eisenmenger’s syndrome. The patient characteristics
(8,10–60) are summarized in Table 1, and the anatomic
defects are presented in Table 2. Worsening of dyspnea and
cyanosis and, occasionally, hemoptysis, cerebrovascular attack,
syncope, chest pain, atrial fibrillation or premature uterine
contractions were indications for hospital admission during
pregnancy. Treatment consisted of bed rest and oxygen sup-
plementation, digoxin (rarely), calcium antagonists and, to
suppress premature uterine contractions or preeclampsia,
magnesium. Three patients died during pregnancy (23,41). Of
70 remaining patients, 33 (47%) delivered at term ($37
weeks), 23 (33%) delivered between weeks 32 and 36 and 14
(20%) delivered #31 weeks. Peripartal management is pre-
sented in Table 3. Hypoxemia, pulmonary hypertensive crisis
and systemic hypotension (in two cases due to oxytocic drugs),
bradycardia, pulmonary thromboembolism, cerebrovascular
attack, convulsions, bleeding with or without anticoagulant
therapy, peripheral vein thrombosis and concomitant peripar-
tal cardiomyopathy influenced postpartal recovery. Vasoactive
Abbreviations and Acronyms
CI 5 confidence interval
OR 5 odds ratio
PAP 5 pulmonary artery pressure
PPH 5 primary pulmonary hypertension
PVD 5 pulmonary vascular disease
SaO2 5 arterial oxygen saturation of hemoglobin
SVPH 5 secondary vascular pulmonary hypertension
Table 1. Characteristics of Parturients With Pulmonary Vascular Disease
Eisenmenger’s Syndrome
(n 5 73)
Primary Pulmonary
Hypertension
(n 5 27)
Secondary Vascular
Pulmonary Hypertension
(n 5 25)
Gravida* 1 (1–4) 2 (1–3) 2 (1–7)
Para $1* 1 (1–3) 2 (1–3) 3 (1–5)
n (%) 17 (23%) 14 (52%) 13 (52%)
Diagnosis made†
Before pregnancy 59 (81%) 7 (26%) 6 (24%)
During pregnancy 11 (15%) 14 (52%) 12 (48%)
Postpartum 3 (4%) 6 (22%) 7 (28%)
Hospital admission (weeks of pregnancy)‡ 28.3 6 6.7 (10–40) 27.6 6 5.6 (15–36) 32.4 6 5.1 (21–39)
At term before delivery† 9 (13%)§ 0 6 (24%)
SaO2 (%)‡ 84.8 6 6.6 (67–98) 91.1 6 7.0 (70–98) 91.4 6 4.5 (82–96)
Hgb (g/dl)‡ 15.7 6 2.5 (10.2–20.4) Not reported 11.5 6 2.2 (8.9–15.9)
PAP, systolic (mm Hg)‡ 108.0 6 25.5 (55–160) 85.3 6 20.4 (50–135) 82.9 6 27.9 (30–135)
PAP, diastolic (mm Hg)‡ 55.2 6 19.7 (12–100) 44.4 6 13.2 (25–70) 37.4 6 17.9 (5–70)
Data presented are *median value (range); †number (%) of patients; or ‡mean value 6 SD (range). §n 5 70. Hgb 5 hemoglobin concentration during pregnancy
(n 5 49); PAP 5 pulmonary artery pressure during pregnancy (systolic value, n 5 81; diastolic value, n 5 70); SaO2 5 arterial oxygen saturation of hemoglobin during
pregnancy (n 5 73).
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drugs, oxygen supplementation, blood transfusion, cessation or
start of anticoagulant therapy, reoperation and hysterectomy
or repair of an atrial septal defect were required postpartum.
Of 26 fatalities (36%) (Fig. 1), 23 women died within 30 days
after delivery (12,13,15,21,22,24,25,27,32–35,37–41,47,51,54).
The cause of death was described as pulmonary hypertensive
crisis with therapy-resistant heart failure (n 5 13), unspecific
“sudden” death (n 5 7), autopsy-confirmed pulmonary throm-
boembolism (n 5 3), cerebral thromboembolism (n 5 1) and
rupture and dissection of the pulmonary artery (n 5 1). Late
maternal death (months postpartum) was reported in two
cases. Live-born neonates (n 5 66, 90%) weighed 2,112 6
876 g. Fetal or early neonatal death due to maternal death or
decompensation, intrauterine growth retardation and/or pre-
mature delivery was reported in six patients (23,26,35,41,
53,56), late neonatal death due to congenital heart disease was
reported in three patients (13,28,32) and neonatal outcome of
two pregnancies was not reported (22,45). The fetal/neonatal
mortality rate in this group was 13% (95% CI 6 to 23).
Primary pulmonary hypertension. The characteristics of
27 parturients (42,61–79) are summarized in Table 1. Dyspnea
at rest and, less frequently, a hoarse voice, hemoptysis, syn-
cope, cyanosis or toxemia of pregnancy indicated hospital
admission during pregnancy. Treatment consisted of bed rest
and oxygen supplementation, digoxin (occasionally), diuretic
agents and vasodilators. Peripartal management is presented
in Table 4. Eleven parturients (41%) delivered at term, 10
(37%) between 32 and 36 weeks and 6 (22%) #31 weeks. Two
survivors delivered during hyperbaric oxygenation (76). Major
postpartal complications were worsening of dyspnea, cyanosis,
hemoptysis, pulmonary hypertensive crisis (in one patient after
use of oxytocin) and systemic hypotension. Eight patients
(30%) died (61,63,64,66,68,70,72,74), all after delivery (Fig. 1),
of therapy-resistant heart failure; only in the case of venooc-
clusive disease were venous thrombi found at autopsy (68).
Table 2. Anatomic Defects of Eisenmenger’s Syndrome (n 5 73)
Isolated ventricular septal defect*† 35 (48%)
Isolated atrial septal defect* 13 (18%)
Isolated patent ductus arteriosus 7 (9%)
Atrial and ventricular septal defect, atrioventricular canal* 5 (7%)
Truncus arteriosus, aortopulmonary window* 3 (4%)
Patent ductus arteriosus with atrial or ventricular septal defect 2 (3%)
Transposition of the great arteries with single ventricle or atrial
and ventricular septal defect*
2 (3%)
Pulmonary atresia with ventricular septal defect and
aortopulmonary collateral channels
2 (3%)
Tetralogy of Fallot, Pott’s anastomosis* 1 (1%)
Not defined 3 (4%)
*In nine patients a cardiac surgical procedure was performed at various
intervals before pregnancy. †In four patients an isolated ventricular septal defect
was surgically closed in childhood. Data presented are number (%) of patients.
Table 3. Management and Outcome of Pregnant Women With
Eisenmenger’s Syndrome (n 5 73)
Maternal
Survival
Maternal
Mortality
No. (%) 47 (64%) 26 (36%)\
95% CI 52–75 25–48
Age (years)* 26.4 6 4.8 (18–37) 24.9 6 4.5 (18–33)
Hospital admission (weeks of
pregnancy)*
26.7 6 6.5 (10–39) 31.4 6 5.9 (21–40)
Toxemia of pregnancy† 2 (4%) 3 (12%)
Delivery (weeks of pregnancy)* 35.1 6 3.5 (26–40) 34.4 6 4.4 (26–40)
Vaginal delivery† 27 (57%) 11 (48%)
Operative delivery† 20 (43%) 12 (52%)\
Monitoring
Noninvasive, not reported† 24 (51%) 15 (63%)
Invasive SAP and/or CVP† 23 (49%) 9 (37%)
Invasive PAP† 8 (17%) 6 (25%)
Anesthesia/analgesia
Not reported† 13 (28%) 5 (22%)
Regional techniques† 22 (47%) 8 (35%)
General anesthesia† 12 (25%) 7 (30%)
Local anesthesia/analgesia† 0 3 (13%)
Oxytocic drugs† 14 (30%) 4 (17%)
Antithrombotic therapy† 28 (60%) 12 (46%)
Neonatal survival† 43 (96%)§ 20 (77%)
95% CI 85–99 56–91
Maternal death, days postpartum
(n 5 23)\
— 5 (0–30)‡
Data presented are *mean value 6 SD (range); †number (%) of patients; or
‡median value (range). §In two cases neonatal outcome was not reported. \Three
patients died before delivery and 23 died after delivery. CI 5 confidence interval;
CVP 5 central venous pressure; PAP 5 pulmonary artery pressure; SAP 5
systemic arterial pressure.
Table 4. Management and Outcome of Pregnant Women With
Primary Pulmonary Hypertension (n 5 27)
Maternal
Survival
Maternal
Mortality
No. (%) 19 (70%) 8 (30%)§
95% CI 50–86 14–50
Age (years)* 25.7 6 5.3 (14–36) 23.3 6 4.4 (18–31)
Hospital admission (weeks of
pregnancy)*
26.9 6 5.5 (15–36) 28.7 6 5.9 (18–36)
Toxemia of pregnancy† 1 (5%) 0
Delivery (weeks of pregnancy)* 35.2 6 3.9 (29–39) 33.3 6 5.4 (26–40)
Vaginal delivery† 12 (63%) 3 (37%)
Operative delivery† 7 (37%) 5 (63%)
Monitoring
Not reported† 8 (42%) 4 (50%)
Invasive SAP and/or CVP† 11 (58%) 4 (50%)
Invasive PAP† 9 (47%) 5 (63%)
Anesthesia/analgesia
Not reported† 8 (42%) 2 (25%)
Regional techniques† 9 (47%) 5 (63%)
General anesthesia† 2 (11%) 1 (13%)
Oxytocic drugs† 7 (37%) 3 (37%)
Antithrombotic therapy† 6 (32%) 3 (37%)
Neonatal survival† 18 (95%) 6 (75%)
95% CI 74–100 35–97
Maternal death, days
postpartum§
— 6 (2–35)‡
Data presented are *mean value 6 SD (range); †number (%) of patients; or
‡median value (range). §All maternal deaths occurred postpartum. Abbrevia-
tions as in Table 3.
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Two late deaths and two heart–lung transplantations were
reported months to years after pregnancy. All neonates
(weight 1,978 6 758 g) were live-born, but three infants (11%
[95% CI 2 to 29]) who were delivered prematurely (66,68,76)
subsequently died.
Secondary vascular pulmonary hypertension. The charac-
teristics of 25 parturients (42,72,80–101) are summarized in
Table 1. The causes, concomitant findings or assumed triggers
of SVPH were Takayasu’s arteritis, pulmonary vasculitis of
connective tissue (lupus erythematosus, scleroderma), sickle
cell disease, illicit and appetite suppressant drugs, chronic
pulmonary thromboembolism, hepatitis, dwarfism with con-
genital hypothyroidism and peripheral pulmonary artery ste-
noses. Dyspnea, syncope (rarely), chest pain, hemoptysis,
systemic hypotension, toxemia of pregnancy or intrauterine
growth retardation led to hospital admission during pregnancy.
Bed rest and oxygen supplementation and, in a few cases,
digoxin, diuretic agents, steroid therapy and nifedipine were
used prepartum. All patients, except for one, delivered at $32
weeks (Table 5). Pulmonary hypertensive crisis after oxytocin
use occurred in one patient. One parturient was treated with
heparin and urokinase; operative delivery was assisted by
extracorporeal circulation; and postpartal treatment with cou-
marin, nifedipine, prostaglandins and diuretic agents led to the
patient’s survival (97). All fatalities (Fig. 1) occurred after
delivery (42,72,81,83,85,86,89,91–96) and were described as
sudden (n 5 7) or progressive (n 5 7) heart failure; no
evidence of new pulmonary thromboembolism was found at
autopsy. Late maternal death, several months postpartum, was
reported in three patients. Twenty-two neonates (weight
2,372 6 640 g) survived. One stillbirth (81) and two neonatal
deaths due to congenital anomalies (88,89) resulted in a
fetal/neonatal mortality rate of 12% (95% CI 3 to 31).
Logistic regression analysis (Table 6). This analysis re-
vealed several risk factors in the Eisenmenger’s syndrome and
SVPH groups and none in the PPH group. Late diagnosis of
PVD and timing of hospital admission (risk increasing by 9%
with each week of pregnancy) were independent risk factors of
maternal mortality for all patients. Operative delivery, severity
of pulmonary hypertension (diastolic rather than systolic PAP)
and number of previous pregnancies and deliveries were
contributing factors. Analysis of maternal mortality showed a
trend toward a significant difference between the PPH and
SVPH groups (p 5 0.06) and between the Eisenmenger’s
syndrome and SVPH groups (p 5 0.08). Neonatal outcome
was significantly influenced by maternal outcome in patients
with Eisenmenger’s syndrome (p , 0.046, OR 4.5) and cumu-
latively in all patients (p , 0.02, OR 3.8).
Discussion
Eisenmenger’s syndrome. In a review of the cases from the
late 1940s to 1978, Gleicher et al. (7) found that 30% of all
pregnancies in patients with Eisenmenger’s syndrome resulted
in maternal death. More recently, an 11% mortality rate in a
London-Torino bicentric study (102); one maternal death
among 26 patients in Trivandrum, India (103); and survival of
all five patients in Hamilton, Ontario, Canada (42) implicate
that the outcome of pregnancy in patients with Eisenmenger’s
syndrome generally improved. However, two maternal deaths,
one abortion and one successful delivery after surgical correc-
tion of congenital heart disease were documented in four
women in Memphis, Tennessee (104). Three of 10 patients
with Eisenmenger’s syndrome died in Sa˜o Paulo, Brasil (41).
The mortality rate of 36% (or 33% if six previous pregnancies
Table 5. Management and Outcome of Pregnant Women With
Secondary Vascular Pulmonary Hypertension (n 5 25)
Maternal
Survival
Maternal
Mortality
n (%) 11 (44%) 14 (56%)§
95% CI 24–65 35–76
Age (years)* 26.1 6 3.5 (17–30) 29.4 6 3.9 (23–34)
Hospital admission (weeks of
pregnancy)*
32.2 6 6.3 (21–39) 32.6 6 4.5 (24–38)
Toxemia of pregnancy† 1 (9%) 3 (21%)
Delivery (weeks of pregnancy)* 36.3 6 2.8 (32–40) 35.9 6 4.5 (29–39)
Vaginal delivery† 8 (73%) 4 (29%)
Operative delivery† 3 (27%) 10 (71%)
Monitoring
Not reported† 5 (45%) 2 (14%)
Invasive SAP and/or CVP† 6 (55%) 12 (86%)
Invasive PAP† 6 (55%) 10 (71%)
Anesthesia/analgesia
Not reported† 5 (46%) 4 (28%)
Regional techniques† 3 (27%) 5 (36%)
General anesthesia† 2 (18%) 5 (36%)
Oxytocic drugs† 4 (36%) 2 (14%)
Antithrombotic therapy† 3 (27%) 10 (71%)
Neonatal survival† 10 (91%) 12 (86%)
95% CI 59–100 57–98
Maternal death, days
postpartum§
— 1 (0–30)‡
Data presented are *mean value 6 SD (range); †number (%) of patients; or
‡median value (range). §All maternal deaths occurred postpartum. Abbrevia-
tions as in Table 3.
Figure 1. Time of maternal death in parturients with Eisenmenger’s
syndrome (n 5 26), PPH (n 5 8) and SVPH (n 5 14). The 0–1 day
postpartal period includes three patients with Eisenmenger’s syn-
drome who died during pregnancy.
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are included) indicates that the risks remained rather un-
changed over the past two decades of experience with Eisen-
menger’s syndrome.
Primary versus secondary vascular pulmonary hyperten-
sion. The classification of PVD syndrome is controversial
(4–6,9,67,105), and PPH is acknowledged to be a pleomorphic
disease whose etiology is unclear (106). Hopkins et al. (6)
recently found that a more favorable hemodynamic profile and
a higher 3-year survival rate are characteristic of patients with
Eisenmenger’s syndrome as compared with patients with PPH.
It was expected that the outcome of late pregnancy between
these groups would similarly differ. However, maternal survival
was comparable in patients with Eisenmenger’s syndrome and
the “pure form” of PPH, in contrast to the mortality rate of
.50% in patients with SVPH. In addition, the outcome
differences were obvious within the heterogeneous group of
patients with SVPH. Pulmonary vasculitis due to systemic
diseases and illicit drug abuse resulted in maternal death in
almost all patients, representing the most malignant form of
PVD, with poor tolerance during pregnancy and postpartal
changes. On the other extreme, in Takayasu’s arteritis and
peripheral pulmonary artery stenoses (right ventricular and
central pulmonary hypertension with protected pulmonary
microcirculation), the pregnancy, delivery and postpartal pe-
riod were experienced without difficulties.
General risk factors and cofactors. Patient age and history
of pregnancy (Table 6) were found to represent potential risk
cofactors of maternal death. Although incompletely reported
and not measured at identical periods during gestation, avail-
able SaO2 and hemoglobin data failed to show any relation to
the outcome in Eisenmenger’s syndrome. PAP values were
incompletely reported as well, and were not measured using
identical methods or at the identical period of pregnancy.
Possibly owing to the missing values, diastolic PAP was a
stronger risk cofactor than systolic PAP in the patients with
Eisenmenger’s syndrome and cumulatively for all patients.
The late diagnosis of PVD and late hospital admission were
the independent risk factors of mortality for patients with
Eisenmenger’s syndrome and cumulatively for all patients. On
average, patients with Eisenmenger’s syndrome and those with
PPH were admitted to the hospital at the beginning of the third
trimester (Tables 1, 3 and 4). The average difference in the
timing of hospital admission was 5 and 2 weeks between
survivors and nonsurvivors in the Eisenmenger and PPH
groups, respectively. Patients with SVPH were admitted 5
weeks later, and no difference was found between survivors
and nonsurvivors (Tables 1 and 5). Thus, earlier diagnosis and
hospital admission and timely preparation of the medical team
have favorably influenced the maternal outcome. Although the
benefits of nitric oxide and prostacyclin therapy (105,106) in
pregnant women with PVD remain to be confirmed, current
therapeutic options look more promising than those available
in the 1978–1996 period.
Management of late pregnancy and delivery. Duration of
pregnancy, timing and mode of delivery, type of anesthesia or
analgesia (with a preference for epidural technique) and type
of maternal monitoring were similarly distributed between
survivors and nonsurvivors. A pulmonary artery catheter was
rarely used in patients with Eisenmenger’s syndrome and more
frequently in those with PPH and SVPH. The peripartal use of
a pulmonary artery catheter in PVD must be questioned owing
to its limited value of providing monitoring information, its
higher potential for complications and its lack of influence on
maternal outcome.
Table 6. Logistic Regression Analysis: p Value and Odds Ratio (95% confidence interval)* for Maternal Outcome as Dependent Variable
Independent Covariable
Univariate Analysis
Multivariate Analysis
(all patients)
Eisenmenger’s
Syndrome
Primary
Pulmonary
Hypertension
Secondary Vascular
Pulmonary
Hypertension All Patients
Age (year) .0.1 .0.1 0.06 .0.1 —
Gravida (n)† .0.1 .0.1 0.052 0.02 0.09
1.52 (1.06–2.17)
Para (n) .0.1 .0.1 .0.1 0.06 —
Late diagnosis† 0.003 .0.1 .0.1 0.001 0.002
6.7 (1.8–24.5) 3.5 (1.6–7.5) 5.4 (2.2–13.4)
Hospital admission† (week) 0.009 .0.1 .0.1 0.003 0.01
1.13 (1.03–1.25) 1.11 (1.04–1.19) 1.09 (1.02–1.19)
PAP, systolic (mm Hg) 0.06 .0.1 .0.1 .0.1 —
PAP, diastolic (mm Hg) 0.01 .0.1 .0.1 0.03 —‡
1.08 (1.02–1.16) 1.03 (1.00–1.06)
Operative delivery† .0.1 .0.1 0.03 0.02 0.07
6.6 (1.1–38.8) 2.4 (1.1–5.2)
Anticoagulant drug .0.1 .0.1 0.03 .0.1 —
6.6 (1.1–38.8)
*Odds ratio and 95% confidence interval were calculated at p , 0.05. For continuous and counting data, the odds ratios are expressed per unit of measurement.
†Gravida, late diagnosis, hospital admission and operative delivery were included in the multivariate analysis. ‡Diastolic value was excluded from the multivariate
analysis owing to a high number of missing values. PAP 5 pulmonary artery pressure.
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Operative delivery was an independent risk factor of ma-
ternal mortality in patients with SVPH and a potential risk
factor for all patients (Table 6). In many patients sudden death
was reported days after delivery, not as a direct consequence
of the operation. Although frequently unavoidable, cesarean
section should be considered a risk (co)factor as it is not the
safest route for delivery (107) in parturients with PVD. The
use of antithombotic drugs remains controversial. These drugs
have caused bleeding, cardiovascular instability and ultimately
maternal death in some patients. Anticoagulation was even
found to be a significant (univariate) risk factor of maternal
mortality in patients with SVPH. In contrast, judicious use
of antithrombotic drugs contributed to survival in a number
of patients with Eisenmenger’s syndrome, PPH and SVPH
(41,42,52,64,65,73,75,80,99).
Timing of maternal death. The first month after delivery
represents the period of highest risk for patients with PVD
(Fig. 1). Longitudinal studies in healthy parturients found the
lowest myocardial contractility at delivery and immediately
postpartum and slow cardiovascular recovery over the next 3
months (108,109). The speculative explanations for predomi-
nant postpartal fatalities in PVD include an increased ten-
dency toward thromboembolism, an exaggerated pulmonary
vascular reactivity and/or a mismatch between declined myo-
cardial contractility and a too sudden decrease in blood volume
after delivery.
Neonatal outcome. Only cases of late pregnancy were
reviewed, and no conclusions can be drawn about the overall
fetal outcome, particularly of early pregnancy, in women with
PVD. A neonatal survival rate of nearly 90% was surprisingly
high. If previous pregnancies are considered, the rate is still
82% in the group with Eisenmenger’s syndrome. The neonatal
outcome depended on maternal tolerance of late pregnancy
and the presence of congenital anomalies, and not on the type
of PVD. Although these survival data are encouraging, the
differences in maternal and neonatal outcome implicate a
“conflict of interest” between the pregnant patient with PVD
and the fetus.
Study limitations. The published data offered only a lim-
ited amount and quality of information. A larger number of
prospectively studied patients would provide a precise pattern
of hemodynamic changes, differentiate the risks of pregnancy
and eventually provide an optimal plan of peripartal manage-
ment. However, the incidence of PVD in late pregnancy is
relatively low. Our systematic search revealed 125 cases re-
ported in the last two decades, and only a few reports provided
detailed information on a series of patients. Some reports,
perhaps including many patients, remain unpublished, and it is
speculative whether the bias to report a successful outcome is
balanced by the negative selection of the most severe cases of
PVD. The review is a quantitative summary of experiences
from various institutions and countries, and the results should
be seen as best available global estimates of the management
and outcome of late pregnancy in women with PVD.
Conclusions. The outcome of pregnant women with Eisen-
menger’s syndrome in the last two decades has not changed
compared with the period before 1978. Maternal mortality
rates of 30% to 36% were almost identical in patients with
PPH and Eisenmenger’s syndrome, whereas the rate was
relevantly higher (.50%) in those with SVPH. Late diagnosis
and late hospital admission were strong independent risk
factors of maternal mortality. Operative delivery, severity of
pulmonary hypertension, number of previous pregnancies and
deliveries and indiscriminate use of anticoagulant drugs must
be considered as contributing risk factors. Almost all maternal
deaths occurred early after delivery; thus, intensive medical
therapy and care should be employed in the highly vulnerable
postpartal period in women with PVD.
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